Johnson & Johnson (JNJ)[Tv]

Key Developments

• FDA De Novo clearance and approval of the OTTAVA™ Robotic Surgical System — This marks a pivotal strategic entry into the high-growth surgical robotics market, positioning Johnson & Johnson as a serious challenger to Intuitive Surgical and redefining its long-term growth narrative beyond traditional pharmaceuticals.
• $5.5 billion settlement to resolve 76,000 talc-related lawsuits — A landmark de-risking milestone that finally closes a 15-year legal overhang, though it exposes JNJ to potential future liability due to the long latency of ovarian cancer, creating lingering reputational and financial risk.
• Record-breaking Q2 2026 financial performance — JNJ reported $25.31 billion in revenue and adjusted EPS of $2.90, surpassing consensus and raising full-year 2026 guidance to a midpoint of $101.1 billion, making it the first time in history JNJ is on track to exceed $100 billion in annual sales.
• Departure of Jennifer Taubert, architect of JNJ’s Innovative Medicines division — Her exit represents a critical leadership vacuum at a time when R&D momentum in oncology and neuroscience is essential, threatening the stability of a key growth engine.
• $13.1 billion acquisition of Shockwave Medical and aggressive bets on next-gen biotech (e.g., $785M Sail Biomedicines partnership) — These moves signal a bold, multi-pronged innovation strategy in MedTech and cutting-edge therapies, aiming to solidify JNJ’s position as a pioneer in regenerative medicine and AI-driven biotech.